Millions of Americans rely on stimulant medications to manage Attention Deficit Hyperactivity Disorder (ADHD), but experts are raising alarms about the limited understanding of the long-term benefits and potential risks associated with these drugs. The issue has gained renewed attention following a severe adverse reaction experienced by a young woman and a coroner's link of a patient's death to his ADHD medication.
Sarah, a 26-year-old who asked to use a pseudonym, described a harrowing experience after switching from lisdexamfetamine (Vyvanse) to methylphenidate (Relexxii) due to insurance coverage issues. She suffered intense vomiting, sweating, a racing heart, and an inability to sleep, symptoms that began shortly after starting the new medication. Believing she was seriously ill, she stopped taking the tablets. Within 24 hours, her symptoms eased, and she gradually recovered over several weeks. This experience left her shaken and questioning the safety of ADHD medications.
ADHD affects an estimated 15.5 million American adults and seven million children, characterized by persistent difficulties with attention, impulsivity, and hyperactivity. While these medications have transformed many lives, psychiatrists note that comprehensive studies on their long-term effects are lacking. The most common ADHD medications—lisdexamfetamine, mixed amphetamine salts (Adderall), and methylphenidate (Ritalin, Concerta)—are stimulants that increase levels of dopamine and norepinephrine in the brain to improve focus and reduce impulsivity.
Growing Prescriptions and Evolving Understanding
ADHD was once primarily viewed as a childhood disorder, but it is increasingly recognized as a lifelong condition. This shift has led to a surge in adult diagnoses and prescriptions. High-profile individuals like Olympic gymnast Simone Biles, actor Tom Holland, and swimmer Michael Phelps have publicly shared their ADHD diagnoses, contributing to greater awareness. This evolving understanding is reflected in prescription rates, which have nearly doubled over the past decade, from 50.4 million in 2012 to 80.8 million in 2023, a 60% increase.
However, some experts argue that this increase in prescribing has outpaced the scientific evidence. "There's no way to know they're safe if you take them for life because we've studied them for at most a few months," stated Professor Joanna Moncrieff. She also questions the clarity of long-term benefits, noting that many individuals do not experience sustained advantages.
Cardiovascular and Neurological Concerns
A significant concern revolves around the potential cardiovascular effects of stimulant medications, which are known to increase heart rate and blood pressure. A 2024 Swedish study involving over 278,000 individuals with ADHD found that taking these drugs for longer than three to five years was associated with a 23% higher risk of cardiovascular disease, particularly high blood pressure. Another study in 2025 indicated that adults with pre-existing heart conditions were more susceptible to cardiovascular side effects.
Dr. Barry K Herman emphasized that while these associations do not prove causation, they highlight the necessity for ongoing monitoring. The American Heart Association recommends thorough cardiovascular assessments before prescribing stimulants. For adults over 40, regular monitoring of vital signs and occasional electrocardiograms are advised.
Additionally, research is exploring a possible link between long-term stimulant use and an increased risk of developing Parkinson's disease or related movement disorders later in life, though evidence remains limited. "The neurological effects are something people need to know about," Professor Moncrieff commented, suggesting this area warrants more attention.
Psychosis and Psychological Effects
While rare, high doses of amphetamine-based ADHD medications have been linked to an increased risk of new-onset psychosis or mania. A study in Iceland tracking over 16,000 adults found that approximately one in 264 patients experienced their first episode of psychosis or mania within a year of starting ADHD medication. Dr. Dan Goodman advised prescribing the lowest effective dose and monitoring patients closely, especially during treatment initiation or dose adjustments.
Some patients also report more subtle psychological changes, such as feeling emotionally blunted or less authentic. Professor Moncrieff suggested that these medications might dampen emotions and reduce lateral thinking and creativity, potentially impacting relationships and empathy.
Questioning Long-Term Efficacy
The long-term effectiveness of ADHD medications is also under scrutiny. While they can improve focus and reduce hyperactivity in the short term, research indicates these immediate benefits may not translate into sustained improvements in academic achievement or quality of life. A 2024 review of 115 meta-analyses found no high-certainty evidence for long-term benefits from any ADHD treatment. The Multimodal Treatment Study of ADHD (MTA), a large long-term trial, found that initial medication benefits largely disappeared by a three-year follow-up, with no long-term advantage observed after sixteen years for those who continued medication compared to those who did not.
Experts stress that this information should not prompt patients to stop their medication abruptly. Instead, they advocate for a balanced perspective, emphasizing that ADHD medications can significantly improve lives when carefully monitored. "When the right medication is matched to the right patient, with regular follow-up and open communication, the benefits often far outweigh the risks," said psychiatric mental health nurse practitioner Dr. Omotolu Aje-Omokore.